Docebo AI Stock Analysis
Docebo (DCBO) AI Stock Analysis
Docebo
(NASDAQ:DCBO)
No summary available
Docebo (DCBO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $749.68M
- Dividend Yield
- 0.00%
- Average Volume (3M)
- 51.46K
- Price to Earnings (P/E)
- 21.8
- Beta (1Y)
- 1.09
- Revenue Growth
- 13.08%
- EPS Growth
- 76.90%
- Country
- US
- Employees
- 966
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Software - Application
Docebo Business Overview & Revenue Model
Company Description
Docebo Inc. develops and provides learning management platform for training in Canada, the United States, and internationally. The company’s cloud platform consists of a learning suite, which includes Docebo Learn platform, a cloud-based learning pla...
Docebo Earnings Call Summary
The call was predominantly positive, characterized by raised full-year revenue growth expectations, 34% EBITDA growth, strong government and healthcare pipeline development, expanding AI and Knowledge capabilities, progress in skills intelligence cross-selling, and continued shareholder returns. The main challenges were delayed government deals, foreign-exchange and enterprise deal-timing effects on Q4 guidance, professional-services mix pressure on gross margins, higher debt following the special dividend, and the early-stage nature of several new initiatives.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Docebo projected full-year 2026 revenue growth at “14% plus,” with subscription revenue growth guided at 12.8% in Q4, following 12% in Q1, 12% in Q2, and 12.4% in Q3; Q4 guidance reflects “almost little to none incremental revenues from Q4 bookings,” with those bookings impacting 2027 guidance to be provided in February. The company expects “20% plus EBITDA margins” while investing in health care, FTE, and government, and said there will be “some EBITDA margin expansion” in 2027 and beyond, with R&D expected to “roughly stay flat as a percentage of revenue” and continued leverage in G&A. Q4 gross margin is expected to show a “similar trend,” while the company expects FedRAMP activity to peak in Q4 this year, with “next Q3” expected to be the highest in the next couple years; the FTE model will be validated over the next 3 to 6 months, and health care is expected to start next year.
Docebo Peers Comparison
Overall Rating
TSE:THNC72Outperform
TSE:OTEX71.9Outperform
TSE:ENGH68Neutral
TSE:NTAR38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | CAD 155.06M | -21.94 | -11.94% | ― | 3.19% | -1907.14% | |
| 72Outperform | CAD 8.54B | 9.30 | 16.15% | 4.32% | -0.64% | 37.53% | |
| 68Neutral | CAD 973.99M | 14.08 | 11.70% | 6.81% | -4.73% | -5.61% | |
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| 38Underperform | CAD 11.83M | -2.86 | 74.69% | ― | 18.40% | 36.36% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DCBO | Docebo, Inc. | 30.05 | 10.97 | 57.48% | |
| TSE:OTEX | Open Text Corporation | 35.37 | -8.89 | -20.08% | |
| TSE:MVY.H | Moovly Media | 0.01 | 0.00 | 0.00% | |
| TSE:ENGH | Enghouse Systems | 18.07 | -0.23 | -1.24% | |
| TSE:NTAR | NexTech AR Solutions Corp | 0.05 | -0.09 | -65.52% | |
| TSE:THNC | Thinkific Labs, Inc. | 2.30 | 0.42 | 22.34% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
